TC
AMPH icon

Trust Company’s Amphastar Pharmaceuticals AMPH Stock Holding History

Trust Company’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$387 Hold
15
– – ﹤0.01% 800
2026
Q2 		$303 Hold
15
– – ﹤0.01% 847
2026
Q1 		$294 Hold
15
– – ﹤0.01% 826
2025
Q4 		$402 Buy
+15
New +$386 ﹤0.01% 758

Other funds holding AMPH

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Trust Company's AMPH Position: Q3 2026 in Review

Trust Company held its Amphastar Pharmaceuticals (AMPH) position steady in Q3 2026 at 15 shares worth $387. The position accounts for ﹤0.01% of the portfolio, ranked #800.

Trust Company first reported a position in AMPH in Q4 2025 and has held it in 4 quarters since. The position peaked at $402 in Q4 2025. 9 funds tracked by Wall St. Rank hold AMPH as of Q3 2026.

  • Trust Company held 15 shares of Amphastar Pharmaceuticals worth $387 as of Q3 2026.
  • Trust Company left its Amphastar Pharmaceuticals share count unchanged in Q3 2026.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Trust Company's portfolio in Q3 2026, its #800 holding.
  • Trust Company first reported a position in Amphastar Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Trust Company's Amphastar Pharmaceuticals position peaked at $402 in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2026.

Based on Trust Company's 13F filing for Q3 2026, filed 9 Oct 2026.